These data validate the use of the ihKA model to test our mechanistic hypothesis of inhibiting USP15 as a therapeutic approach to modulate pathways that play an important role in epilepsy (NRF2, IFN-α/β, and TGF-β). Here, IFNA1 is linked to epilepsy.